Trial Profile
A multi-centre long-term follow-up study of patients with low-grade non-Hodgkin's lymphoma previously treated with iodine I 131 tositumomab in studies CP-97-011, CP-98-025, CP-99-032, or CP-99-036
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GSK
- 29 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2008 New trial record.